A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Lymphoma

Trial Profile

A multicenter, phase III, randomized study to evaluate the efficacy of a response-adapted strategy to define maintenance after standard chemoimmunotherapy in patients with advanced-stage Follicular Lymphoma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2013

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
  • Indications Follicular lymphoma
  • Focus Therapeutic Use
  • Acronyms FIL-FOLL12
  • Most Recent Events

    • 27 Aug 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top